Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?

Sâada-Bouzid, Esma; Peyrade, Fréd́eric; Guigay, J.

doi:10.1097/cco.0000000000000834

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though major advances have been made in the treatment of recurrent or metastatic HNSCC (RM HNSCC), the outcome of those patients remains poor. In first-line RM HNSCC, several options are discussed according to the performans status, the eligibility to high-dose cisplatin and tumor programmed death ligand 1 expression [4][5][6][7]. Anti-programmed death 1 (PD1) checkpoint inhibitors were first approved in second line and then in first line [4,8,9].…”

Section: Introductionmentioning

confidence: 99%

Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?

Yahia

Petit

Sâada-Bouzid

2023

Current Opinion in Oncology

Self Cite

View full text Add to dashboard Cite

Purpose of reviewDespite recent advances, treatment personalization remains an issue for recurrent metastatic head and neck squamous cell carcinoma (RM HNSCC) patients. After human papilloma virus (HPV) and programmed death ligand 1 (PDL1) expression, Harvey rat sarcoma viral oncogene homolog (HRAS) appears as an emerging target in this field. In this review, we summarize the features of HRAS-mutated HNSCC and its targeting by farnesyl transferase inhibitors. Recent findingsHRAS mutations define a small subgroup of RM HNSCC patients with a poor prognosis and often refractory to the standard treatments. Posttranslational processing of HRAS being dependent on farnesylation, farnesyl transferase inhibitors have been evaluated in HRAS-mutated tumors. Tipifarnib, a first in class farnesyl transferase inhibitor, has shown efficacy in phase 2 trials with HRAS-mutated tumors. Despite reported high response rates in selected population, the efficacy of Tipifarnib is inconsistent and always transient, probably because of limiting hematological toxicities leading to dose reduction and occurrence of secondary resistance mutations. SummaryTipifarnib is the first in the class of farnesyl transferase inhibitors to show efficacy in HRAS-mutated RM HNSCC. The understanding of mechanisms of resistance will pave the way for the design of secondgeneration farnesyl transferases inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?

Yahia

Petit

Sâada-Bouzid

2023

Current Opinion in Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Curcumin Enhances the Efficacy of Docetaxel by Promoting Anti-Tumor Immune Response in Head and Neck Squamous Cell Carcinoma

Sun

Yao

Liu

et al. 2023

Cancer Investigation

View full text Add to dashboard Cite

Current Therapeutic Strategies for Patients with Hypopharyngeal Carcinoma: Oncologic and Functional Outcomes

Bozec

Poissonnet

Dassonville

et al. 2023

JCM

View full text Add to dashboard Cite

Hypopharyngeal cancer is usually diagnosed at an advanced stage and is associated with a high risk of recurrence and poor survival rates. Although they differ greatly in terms of prognosis, hypopharyngeal cancers are usually treated together with laryngeal cancers in clinical trials. Therefore, there are very few studies that focus specifically on patients with hypopharyngeal carcinoma. As a result, the therapeutic management of these patients is highly debated, and their clinical outcomes are poorly reported. The aim of this review is therefore to discuss the current therapeutic options in patients with hypopharyngeal carcinoma and their oncologic and functional outcomes. Patients with early-stage tumors can be treated either by conservative surgery (including transoral robot-assisted surgery) or by RT alone. However, most patients are diagnosed with locally advanced tumors that cannot be treated surgically without total laryngectomy. In this situation, the critical issue is to select the patients eligible for a larynx preservation therapeutic program. However, radical surgery with total laryngectomy still plays an important role in the management of patients with hypopharyngeal carcinoma, either as the primary treatment modality (T4 resectable primary tumor, contraindication to larynx preservation therapies) or, more commonly, as salvage treatment.

show abstract

Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?

Cited by 3 publications

References 33 publications

Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?

Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?

Curcumin Enhances the Efficacy of Docetaxel by Promoting Anti-Tumor Immune Response in Head and Neck Squamous Cell Carcinoma

Current Therapeutic Strategies for Patients with Hypopharyngeal Carcinoma: Oncologic and Functional Outcomes

Contact Info

Product

Resources

About